M. Matsuda (Kure, Hiroshima JP)
Background and Aims: Obesity-induced chronic low-grade inflammation is causally associated with insulin resistance leading to dyslipidemia, which is residual risks for coronary artery diseases (CAD) in patients on statin therapy. The aim of this study is to clarify the impacts of adipocytokines and obesity-associated inflammatory markers on apolipoprotein (apo) A1 and B in patients on statin therapy.
Methods: In 156 patients on statin therapy (age, 70±10 years; male, 73%; low-density lipoprotein cholesterol, 93±22 mg/dL), serum levels of apoA1 and apoB, high-sensitive C-reactive protein (hs-CRP), interleukin 6 (IL-6) and adipocytokines including adiponectin, leptin and resistin were measured using respective ELISAs.
Results: Serum apoA1 levels were significantly correlated with serum adiponectin (p<0.0001) and resistin (p<0.001), but not with leptin. Inflammatory markers such as hs-CRP (p=0.003) and IL-6 (p<0.0001) showed strong impacts on apoA1 levels. In multivariate logistic analysis, IL-6 (p=0.004) and adiponectin (p=0.02) were significant determinants for apoA1 levels. On the other hand, serum apoB levels were significantly associated with serum leptin (p<0.001), but not with other adipocytokines or inflammatory markers.
Conclusions: IL-6 and adiponectin are strong determinants for apoA1 level, and leptin is an important factor for apoB level in patients on statin therapy.